Skip to main content

Clinical Trial Search Results

Clinical Trial Search Results

Showing 1-9 out of 358 results.
NCT03429543

A double-blind, randomised, placebo-controlled, parallel group trial to evaluate the efficacy and safety of empagliflozin and linagliptin over 24 weeks, with a double-blind active treatment safety extension period to 52 weeks, in children and adolescents with type 2 diabetes mellitus

Icon for trial | 1218-0091 A double-blind, randomised, placebo-controlled, parallel group trial to evaluate the efficacy and safety of empagliflozin and linagliptin over 24 weeks, with a double-blind active treatment safety extension period to 52 weeks, in children and ad

This study is currently enrolling.

This study is being done to: (a) compare the safety and effects of the study drugs, called empagliflozin and linagliptin with a placebo, in children and adolescents with type 2 diabetes, during the first 25 weeks of this study. ...

NCT03856099

A Multicenter, Open-Label, Phase Ⅱ Clinical Trial to Evaluate the Safety and Efficacy of TTAC-0001, a Fully Human Monoclonal Antibody in Patients with Recurrent Glioblastoma Progressed on Bevacizumab Including Therapy

Icon for trial | PMC_TTAC-0001_03 A Multicenter, Open-Label, Phase Ⅱ Clinical Trial to Evaluate the Safety and Efficacy of TTAC-0001, a Fully Human Monoclonal Antibody in Patients with Recurrent Glioblastoma Progressed on Bevacizumab Including Therapy

This study is currently enrolling.

The aim of this study is to assess the safety and effectiveness of the study drug, TTAC-0001 to patients with recurrent glioblastoma which has progressed on bevacizumab treatment. Another aim is to measure the levels of TTAC-00 ...

NCT03398135

A Multicenter, Randomized, Double-Blind, Placebo-Controlled 52-Week Maintenance and an Open Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065

Icon for trial | M16-066 A Multicenter, Randomized, Double-Blind, Placebo-Controlled 52-Week Maintenance and an Open Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16

This study is currently enrolling.

The purpose of this study is to evaluate the efficacy and safety of Risankizumab versus placebo and determine how well it works as maintenance therapy and long-term therapy for subjects with moderate to severe ulcerative coliti ...